Medscape July 22, 2024
Several clinical trials in colorectal cancer (CRC) have started recruiting recently. Could one of your patients benefit from participating?
Previously treated metastatic CRC. Adult patients with this type of cancer may be eligible for a National Cancer Institute open-label phase 1/2 study testing a novel vaccine-based regimen that targets a protein on the surface of CRC cells and recruits the immune system to fight the tumor.
For up to 2 years, all study participants will receive intravenous (IV) retifanlimab (Zynyz) and an injection of N-803 (Anktiva) every 4 weeks. They will also receive TriAdeno vaccine injections every 4 weeks for three cycles and then every 12 weeks. A subset of people will also take daily tablets of SX-682, an enhancer...
Today's Sponsors
Today's Sponsor